1. What Is the Methylation Liquid Biopsy Market?
The Methylation Liquid Biopsy Market comprises blood-based assays that analyze DNA methylation patterns in circulating cell-free DNA to detect cancer, classify tumor tissue of origin, and screen asymptomatic populations. The market includes bisulfite sequencing platforms, methylation-specific PCR assays, reduced representation bisulfite sequencing kits, and machine learning classification algorithms for methylation-based cancer signals. These assays serve cancer screening programs, oncologists, and clinical diagnostic developers performing multi-cancer early detection, tissue-of-origin classification, and epigenomic biomarker research. The scope excludes genetic mutation-based ctDNA assays, intact CTC isolation approaches, and cancer protein immunoassays that detect cancer signals through distinct non-epigenomic mechanisms.
2. Methylation Liquid Biopsy Market Size & Forecast
3. Emerging Technologies
- Deep learning methylation classifiers trained on multi-tissue reference databases are advancing to distinguish cancer-derived methylation signals from age-related and inflammation-associated cfDNA patterns. Growing deployment of deep learning models is improving cancer signal specificity and reducing false positive rates in general population methylation screening.
- Long-read single-molecule methylation sequencing technology is advancing to resolve methylation patterns at haplotype phase in individual cell-free DNA molecules. Increasing application of long-read methylation sequencing is improving haplotype-resolved methylation analysis and enabling allele-specific cancer methylation signature detection.
- cfMeDIP enrichment combining methylation-specific immunoprecipitation with low-input sequencing is advancing to improve sensitivity for sparse cancer methylation signals at early tumor stages. Continued development of enrichment-based methylation assays is improving cancer detection in samples where tumor fraction is very low relative to background cell-free DNA.
- Methylation clock biomarker analysis using epigenetic age acceleration signatures is advancing to identify individuals at elevated cancer risk from blood methylation patterns. Expanding methylation clock applications are generating risk stratification tools that complement binary cancer screening calls with continuous cancer risk probability estimates.
Such innovations are driving change across adjacent industries too. Discover more in our Liquid Biopsy Circulating Tumor Cell Market.
4. Key Market Opportunity
One of the key opportunities in the Methylation Liquid Biopsy Market is the validation and reimbursement of multi-cancer early detection screening for average-risk individuals aged 45-plus whose cancer burden justifies population-scale preventive blood testing. Many cancers are detected at late stage since single-organ screening is impractical for all tumor types, leaving a large proportion of the cancer burden without effective early detection. Advances in methylation classifier specificity, large prospective trial evidence, and health system economic modeling are building the reimbursement case for population-scale multi-cancer screening programs. Diagnostic companies achieving payer coverage for methylation multi-cancer screening stand to generate very large annual testing volumes across the preventive health population.
5. Top Companies in the Methylation Liquid Biopsy Market
The following organisations hold leading positions in the Methylation Liquid Biopsy Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Grail (Galleri)
- Singlera Genomics
- Guardant Health (Guardant Infinity)
- Exact Sciences
- Volition
- CancerSEEK (Johns Hopkins)
- Nipd Genetics
- Burning Rock Biotech
- Berry Oncology
- New Horizon Health
- Roche
- Illumina
6. Market Segmentation
The Methylation Liquid Biopsy Market is analysed across 7 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Methylation Assay | Bisulfite Sequencing WGBS Whole Genome Bisulfite Sequencing Targeted Bisulfite Sequencing Methylation-Specific PCR cfMeDIP Enrichment Methylated DNA Immunoprecipitation Sequencing |
| By Application | Multi-Cancer Early Detection Pan-Cancer Screening Tissue of Origin Classification Minimal Residual Disease Immunotherapy Response Prediction |
| By Cancer Type Screened | Colorectal Cancer Lung Cancer Breast Cancer Pancreatic Cancer Multi-Cancer Panel |
| By Sample Type | Plasma Cell-Free DNA Serum Cell-Free DNA Urine cfDNA |
| By Algorithm Type | Machine Learning Classifier Logistic Regression Model Neural Network Classifier Ensemble Multi-Marker Model |
| By End User | Cancer Screening Programs Academic Cancer Centers Health System Oncology Pharmaceutical Companion Diagnostics General Population Screening |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Methylation Liquid Biopsy Market trajectory over the forecast period:
Multi-Cancer Early Detection Blood Tests Are Creating a New Cancer Screening Category.Methylation-based multi-cancer screening is establishing a novel preventive oncology workflow that complements existing organ-specific screening with a single annual blood draw. Grail advanced its Galleri multi-cancer early detection blood test commercial rollout in 2024, expanding direct-to-physician and health system access for multi-cancer methylation screening.
Epigenomic Tissue-of-Origin Classification Is Improving Cancer Localization for Incidentalomas and CUP.Oncologists are using methylation-based tissue-of-origin classifiers to identify the primary tumor site in cancer of unknown primary and guide focused diagnostic workup after imaging is inconclusive. Singlera Genomics progressed its methylation-based cancer tissue-of-origin classification panel in 2024, advancing clinical adoption for cancer of unknown primary workup programs.
NHS and National Health System Evaluation Programs Are Building Multi-Cancer Screening Evidence.National health systems are conducting large prospective trials to assess the performance and cost-effectiveness of methylation liquid biopsy screening before population-wide implementation decisions. Grail progressed the NHS-Galleri trial data analysis in 2024, advancing evidence for the clinical benefit of methylation-based multi-cancer detection in an asymptomatic general population cohort.
For related market intelligence, see the Liquid Biopsy Circulating Tumor Dna Market.
8. Segmental Analysis
By Application, multi-cancer early detection dominated the Methylation Liquid Biopsy Market in 2025, driven by the commercial launch of Galleri and other pan-cancer screening products in the United States. Clinical programs continue directing methylation liquid biopsy investment toward early detection owing to the large clinical need and substantial commercial potential of cancer screening. Tissue of origin classification is the fastest-growing Application category, driven by oncologist demand for cancer primary site identification in patients presenting with cancer of unknown primary. Oncologists are advancing methylation tissue classification as the test improves diagnostic accuracy and reduces the invasive workup burden for cancer of unknown primary patients.
By Algorithm Type, machine learning classifier dominated the Methylation Liquid Biopsy Market in 2025, reflecting the use of trained models for cancer signal detection in multi-cancer screening products. Diagnostic developers continue specifying ML classifiers owing to their performance advantage over conventional statistical models in distinguishing cancer methylation signals from biological noise. Neural network classifier is the fastest-growing Algorithm Type category, driven by deep learning advances improving methylation pattern recognition from complex high-dimensional sequencing data. Developers are advancing neural network models as training dataset size grows and architecture improvements increase cancer detection sensitivity at lower false positive rates.
9. Regional Analysis
Regional demand patterns across the Methylation Liquid Biopsy Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Methylation Liquid Biopsy Market in 2025, with a market share of 50.2%. Grail's Galleri test commercialization, multiple US academic center methylation research programs, and the largest oncology clinical trial infrastructure globally are anchoring North American leadership. US health system adoption of Galleri and investment from major payers evaluating multi-cancer screening coverage are driving commercial deployment ahead of other geographies. NIH-funded methylation biomarker research and FDA engagement on multi-cancer early detection regulatory pathways are accelerating evidence generation for US population screening authorization.
Highest CAGR Region
Europe is expected to register the highest CAGR of 32.40% during the forecast period. NHS-Galleri trial progress, European health system interest in cost-effective cancer prevention, and growing academic methylation research across Germany, Sweden, and the Netherlands are driving demand. European national cancer plans emphasizing early detection and health system efficiency are creating favorable policy environments for population-scale liquid biopsy screening evaluation. CE mark pathways and European methylation research programs are generating the clinical evidence required for national health authority consideration of multi-cancer screening adoption.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Methylation Liquid Biopsy Market was valued at USD 584.30 Mn in 2025 and is projected to reach USD 5,093.50 Mn by 2034, growing at a CAGR of 27.20% over the 2026–2034 forecast period.
The Methylation Liquid Biopsy Market is projected to grow at a CAGR of 27.20% from 2026 to 2034.
North America dominated the Methylation Liquid Biopsy Market in 2025, with a market share of 50.2%.
The leading companies in the Methylation Liquid Biopsy Market include Grail (Galleri), Singlera Genomics, Guardant Health (Guardant Infinity), Exact Sciences, Volition, CancerSEEK (Johns Hopkins), Nipd Genetics, Burning Rock Biotech, Berry Oncology, New Horizon Health, Roche, Illumina.
Multi-cancer early detection blood tests are creating a new cancer screening category.
By Application, multi-cancer early detection dominated the Methylation Liquid Biopsy Market in 2025, driven by the commercial launch of Galleri and other pan-cancer screening products in the United States.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.